Hims & Hers shares surge as Novo Nordisk drops GLP-1 lawsuit
The Danish drugmaker's decision removes a legal overhang tied to the telehealth firm's handling of semaglutide offerings.
DO
By Daniel Okafor · Regulatory Correspondent
Sep 3 03:00 ETSource: FirstWord Pharma
The wire
- 01FirstWord Pharma reports Novo Nordisk has dropped its GLP-1 litigation against Hims & Hers, sending the telehealth company's shares higher.
- 02Telehealth operators selling or marketing semaglutide-adjacent products have been watching this case as a marker of how aggressively Novo polices its brand and supply chain.
- 03Terms and the reasoning behind the dismissal were not detailed in the report; whether other manufacturer actions against telehealth sellers continue is unresolved.
From the source
Read at firstwordpharma.comHims & Hers Health shares surge as Novo Nordisk drops GLP-1 lawsuit
Source URL https://firstwordpharma.com/story/7131035